PRELUDE THERAPEUTICS INC Basic Shares Outstanding (Weighted Average)
PRELUDE THERAPEUTICS INC (PRLD) reported Basic Shares Outstanding (Weighted Average) of 98.39 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 98.39M shares, a 29.47% increase year-over-year.
- PRELUDE THERAPEUTICS INC weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 82.52M shares, a 8.60% increase year-over-year.
- PRELUDE THERAPEUTICS INC weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 79.71M shares, a 5.06% increase year-over-year.
- PRELUDE THERAPEUTICS INC weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 76.13M shares, a 0.36% increase year-over-year.
- PRELUDE THERAPEUTICS INC weighted average number of shares outstanding, basic for fiscal 2025 was 76.96M shares, a 1.52% increase from fiscal 2024.
- PRELUDE THERAPEUTICS INC weighted average number of shares outstanding, basic for fiscal 2024 was 75.81M shares, a 25.60% increase from fiscal 2023.
- PRELUDE THERAPEUTICS INC weighted average number of shares outstanding, basic for fiscal 2023 was 60.36M shares, a 27.41% increase from fiscal 2022.
- PRELUDE THERAPEUTICS INC weighted average number of shares outstanding, basic for fiscal 2022 was 47.37M shares, a 2.87% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 98.39M shares 10-Q · filed 2026-08-11 | 90.50M shares 10-Q · filed 2026-08-11 | 86.87M shares derived: average of 3 quarters · filed 2026-08-11 | 84.19M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 82.52M shares 10-Q · filed 2026-05-12 | 81.12M shares derived: average of 2 quarters · filed 2026-05-12 | 79.45M shares derived: average of 3 quarters · filed 2026-05-12 | 78.59M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | 79.71M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 77.92M shares derived: average of 2 quarters · filed 2026-03-10 | 77.28M shares derived: average of 3 quarters · filed 2026-08-11 | 76.96M shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 76.13M shares 10-Q · filed 2025-11-12 | 76.06M shares derived: average of 2 quarters · filed 2026-08-11 | 76.04M shares 10-Q · filed 2025-11-12 | 76.00M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | 75.99M shares 10-Q · filed 2026-08-11 | 75.99M shares 10-Q · filed 2026-08-11 | 75.95M shares derived: average of 3 quarters · filed 2026-08-11 | 75.93M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | 75.99M shares 10-Q · filed 2026-05-12 | 75.93M shares derived: average of 2 quarters · filed 2026-05-12 | 75.90M shares derived: average of 3 quarters · filed 2026-05-12 | 75.87M shares derived: average of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | 75.87M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 75.86M shares derived: average of 2 quarters · filed 2026-03-10 | 75.83M shares derived: average of 3 quarters · filed 2026-03-10 | 75.81M shares 10-K · filed 2026-03-10 |
| 2024-09-30 | 75.86M shares 10-Q · filed 2025-11-12 | 75.81M shares derived: average of 2 quarters · filed 2025-11-12 | 75.78M shares 10-Q · filed 2025-11-12 | 74.24M shares derived: average of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | 75.76M shares 10-Q · filed 2025-08-14 | 75.75M shares 10-Q · filed 2025-08-14 | 73.70M shares derived: average of 3 quarters · filed 2025-08-14 | 72.18M shares derived: average of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | 75.74M shares 10-Q · filed 2025-05-06 | 72.66M shares derived: average of 2 quarters · filed 2025-05-06 | 70.99M shares derived: average of 3 quarters · filed 2025-05-06 | 67.30M shares derived: average of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | 69.59M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | 68.62M shares derived: average of 2 quarters · filed 2025-03-10 | 64.49M shares derived: average of 3 quarters · filed 2025-03-10 | 60.36M shares 10-K · filed 2025-03-10 |
| 2023-09-30 | 67.64M shares 10-Q · filed 2024-11-06 | 61.94M shares derived: average of 2 quarters · filed 2024-11-06 | 57.28M shares 10-Q · filed 2024-11-06 | 54.83M shares derived: average of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | 56.24M shares 10-Q · filed 2024-08-12 | 52.01M shares 10-Q · filed 2024-08-12 | 50.56M shares derived: average of 3 quarters · filed 2024-08-12 | 49.78M shares derived: average of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | 47.74M shares 10-Q · filed 2024-05-07 | 47.71M shares derived: average of 2 quarters · filed 2024-05-07 | 47.63M shares derived: average of 3 quarters · filed 2024-05-07 | 47.54M shares derived: average of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | 47.69M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | 47.57M shares derived: average of 2 quarters · filed 2024-02-15 | 47.47M shares derived: average of 3 quarters · filed 2024-02-15 | 47.37M shares 10-K · filed 2024-02-15 |
| 2022-09-30 | 47.45M shares 10-Q · filed 2023-11-01 | 47.36M shares derived: average of 2 quarters · filed 2023-11-01 | 47.27M shares 10-Q · filed 2023-11-01 | 47.12M shares derived: average of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | 47.28M shares 10-Q · filed 2023-08-03 | 47.17M shares 10-Q · filed 2023-08-03 | 47.01M shares derived: average of 3 quarters · filed 2023-08-03 | 46.84M shares derived: average of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | 47.07M shares 10-Q · filed 2023-05-08 | 46.87M shares derived: average of 2 quarters · filed 2023-05-08 | 46.69M shares derived: average of 3 quarters · filed 2023-05-08 | 46.53M shares derived: average of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | 46.68M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 46.50M shares derived: average of 2 quarters · filed 2023-03-15 | 46.35M shares derived: average of 3 quarters · filed 2023-03-15 | 46.05M shares 10-K · filed 2023-03-15 |
| 2021-09-30 | 46.33M shares 10-Q · filed 2022-11-14 | 46.19M shares derived: average of 2 quarters · filed 2022-11-14 | 45.84M shares 10-Q · filed 2022-11-14 | |
| 2021-06-30 | 46.06M shares 10-Q · filed 2022-08-09 | 45.59M shares 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |